Compare Pinterest Inc (PINS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pinterest Inc vs Viatris Inc — how do they compare? Pinterest Inc trades at $21.38 (market cap $11.63B), while Viatris Inc trades at $17.62 (market cap $20.03B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays a 2.75% dividend while Pinterest Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pinterest Inc for 85 Days and Viatris Inc for 57 Days on average.
| PINS | VTRS | |
|---|---|---|
Market Cap | $11.63B | $20.03B |
Volume | 12,792,940 | 14,109,977 |
Sector | Media | Health |
52-Week High | $35.24 | $18.27 |
52-Week Low | $15.42 | $9.74 |
Typical Hold Time | 85 Days | 57 Days |
Enterprise Value | $11.55B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pinterest (PINS) trades at $21.35, up 5.1% today, showing strong momentum after three consecutive earnings beats. The stock maintains a bullish technical outlook with positive moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, revenue growth accelerated to $4.22 billion in 2025 with improving profitability, though valuation multiples remain elevated with a P/E of 60.4. Recent news highlights the company's visual search ad innovations and international monetization progress.
The outlook remains positive with 54% analyst buy ratings and a $27.93 consensus price target representing 31% upside. Key opportunities include continued international ARPU growth and AI-driven advertising enhancements. Risks include competitive pressure from larger platforms, potential advertising slowdowns, and insider selling activity that may signal caution among company leadership.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
